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ABSTRACT
The toxicity of hexavalent chromium [Cr(VI)] in drinking water has been studied extensively, and available in vivo and in
vitro studies provide a robust dataset for application of advanced toxicological tools to inform the mode of action (MOA).
This study aimed to contribute to the understanding of Cr(VI) MOA by evaluating high-throughput screening (HTS) data and
other in vitro data relevant to Cr(VI), and comparing these findings to robust in vivo data, including transcriptomic profiles in
target tissues. Evaluation of Tox21 HTS data for Cr(VI) identified 11 active assay endpoints relevant to the Ten Key
Characteristics of Carcinogens (TKCCs) that have been proposed by other investigators. Four of these endpoints were
related to TP53 (tumor protein 53) activation mapping to genotoxicity (KCC#2), and four were related to cell death/
proliferation (KCC#10). HTS results were consistent with other in vitro data from the Comparative Toxicogenomics Database.
In vitro responses were compared to in vivo transcriptomic responses in the most sensitive target tissue, the duodenum, of
mice exposed to180 ppm Cr(VI) for 7 and 90 days. Pathways that were altered both in vitro and in vivo included those
relevant to cell death/proliferation. In contrast, pathways relevant to p53/DNA damage were identified in vitro but not
in vivo. Benchmark dose modeling and phenotypic anchoring of in vivo transcriptomic responses strengthened the finding
that Cr(VI) causes cell stress/injury followed by proliferation in the mouse duodenum at high doses. These findings
contribute to the body of evidence supporting a non-mutagenic MOA for Cr(VI)-induced intestinal cancer.
Key words: dose–response modeling; hexavalent chromium; high-throughput screening; mode of action; transcriptomics;
risk assessment.
There is increasing impetus towards transforming toxicity test-
ing and the assessment of potential human health risks
through incorporation of new technologies, including high-
throughput screening (HTS), toxicogenomics, bioinformatics,
systems biology, and computational toxicology (NRC, 2007;
Richard et al., 2016). The continued expansion of HTS data
through the ToxCast/Tox21 consortium has resulted in a large
publicly available repository of in vitro toxicity data currently
spanning >1800 chemicals, generated with the goal of support-
ing the development of improved toxicity prediction (Richard
et al., 2016). Toxicogenomic analyses have also become increas-
ingly prevalent as a result of decreasing costs and increasing
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feasibility of genome-wide screening technologies (Fry, 2015).
Strategies to incorporate these methods and corresponding
datasets into assessments of potential human health risks and
regulatory decisions are current topics of growing interest
(Bourdon-Lacombe et al., 2015; Moffat et al., 2015; Richard et al.,
2016); however, more studies are still needed to evaluate the re-
quired steps and utility of such efforts.
In 2008, findings were released from a 2-year cancer bioassay
in mice and rats exposed to hexavalent chromium [Cr(VI)] in
drinking water (NTP, 2008). These studies indicated that Cr(VI)
induced tumors in the small intestines of mice and in the oral
mucosa of rats. A comprehensive research program was subse-
quently initiated to investigate the mode of action (MOA) under-
lying the tumorigenic responses observed in these target
tissues. This MOA research program has resulted in the genera-
tion of an extensive body of histopathologic, pharmacokinetic,
genotoxic, and biochemical data from the carcinogenic target
tissues in rats and mice (Cullen et al., 2016; O’Brien et al., 2013;
Thompson et al., 2012, 2015a,b,c). Transcriptomic data were also
collected in target tissues after both short-term (7 days) and
long-term (90 days) exposures (Kopec et al., 2012a,b). This rich
dataset affords the opportunity to compare in vivo toxicity re-
sponses to Cr(VI) to in vitro high throughput and high content
data.
Cr(VI) is a known human carcinogen by inhalation and has
long been recognized as genotoxic, based primarily on in vitro data
(IARC, 1990), and, primarily for these reasons, it has been assumed
that Cr(VI) acts by a directly genotoxic MOA in causing tumors at
all sites (OEHHA, 2011; U.S. EPA, 2010). However, more recent re-
search has shown that Cr(VI) does not increase mutant frequency
in the oral cavity of rats (Thompson et al., 2015c), and that Cr(VI)
causes intestinal tumors by chronic cytotoxicity in intestinal villi
leading to chronic regenerative hyperplasia that increases the risk
of crypt stem cell transformation and tumorigenesis (Thompson
et al., 2013). Some regulatory agencies have used these data to sup-
port the development of threshold toxicity criteria for the intestinal
tumors (Health Canada, 2015; TCEQ, 2016).
The Tox21 consortium recently released in vitro bioactivity
data for Cr(VI) that has yet to be incorporated into the under-
standing of Cr(VI) MOA for tumorigenic responses. The current
study set out to do the following: (1) to analyze these recently
generated HTS data and compare results against a large reposi-
tory of public literature [ie, the Comparative Toxicogenomic
Database (CTD)] to evaluate consistency between in vitro re-
sponses to Cr(VI); (2) to update the data processing, statistical
analysis, and dose–response modeling of transcriptomics data
originally published by Kopec et al. (2012a); and (3) to evaluate
the utility of the HTS in vitro data for purposes of informing the
Cr(VI) MOA by comparing the in vitro responses to the in vivo re-
sponses at the pathway-level across all doses evaluated. Study
findings contribute to the growing understanding of Cr(VI) MOA
while demonstrating potential strengths and limitations of in vi-
tro HTS data in the context of risk assessment.
MATERIALS ANDMETHODS
Tox21 data collection and organization. In vitro HTS data for Cr(VI),
in the form of sodium dichromate dihydrate (SDD), are available
through the Tox21 consortium, a federal collaboration between
the National Toxicology Program at the National Institute of
Environmental Health Sciences and the National Center for
Advancing Translational Sciences, the Food and Drug
Administration, and the United States Environmental
Protection Agency (U.S. EPA). For the current investigation,
processed Tox21 data for SDD were extracted from the U.S.
EPA’s Summary Files (invitrodb_v2, released Oct 2015) (U.S. EPA,
2015), including assay summary activity (hit) call, AC50 (concen-
tration at which the activity reaches 50% of its maximal values
for an assay-chemical pair), Z-score (indicator of the distance
from cytotoxicity distribution), and cytotoxicity data. It should
be noted that there are several additional ways to access the
Tox21 database [eg, through the National Institutes of Health
(NIH) website]. However, the resource provided through the U.S.
EPA was used because, at the time of the analysis, it represented
the most accessible route to the data and provided other
summary-level assay statistics such as the hit calls, AC50 values,
and Z-scores, described in further detail below. No data were
available for SDD in the ToxCast assay suite.
Chemical-assay activity was characterized by hit calls, repre-
sented by values of 1, 0, or 1. A value of 1 indicated an “active”
chemical, a value of 0 indicated an “inactive” chemical, and a
value of 1 indicated that the activity could not be determined.
Hit calls were based on criteria previously defined by the U.S.
EPA (Judson et al., 2015, 2016). Z-scores were also used to evalu-
ate the relationship between chemical-assay activity and assay
cytotoxicity distributions. A higher Z-score (eg, Z-score> 2) indi-
cated assay activity that occurred at a concentration far below
the “cytotoxic signal burst” region, and a lower Z-score (eg,
Z-score 2) indicated assay activity that occurred at a concen-
tration at or above the “cytotoxic signal burst” region (Judson
et al., 2016). As was implemented in a recent evaluation of
ToxCast data (Auerbach et al., 2016), chemical-assay pairs with
Z-scores  2 were excluded to account for this potential cytotox-
icity interference. It is notable that a Z-score cutoff of 3 has
recently been proposed (Judson et al., 2016); however, a Z-score
of 2 was selected for the purposes of the current investigation to
increase inclusivity in potential assay activity results. Tox21
data were also evaluated in the context of the Ten Key
Characteristics of Carcinogens (TKCC) recently proposed by
Smith et al. (2016), using assay-characteristic mappings previ-
ously implemented by the International Agency for Research on
Cancer (IARC) in Monograph Volume 112 (IARC, 2015).
Identifying in vitro responses to Cr(VI) with comparative toxicogenom-
ics database. In order to compare Tox21 HTS results to other pre-
vious in vitro findings, the CTD was queried for chemical-gene/
protein interactions relevant to Cr(VI). The CTD is a publicly
available database containing manually curated information on
chemical-gene-disease relationships from previously published
scientific literature (Davis et al., 2015). At the time of the analy-
sis, CTD contained 42 000 genes (spanning 565 organisms) and
12 000 chemicals, resulting in 1.4 million curated chemical-
gene/protein interactions. The following Cr(VI)-relevant com-
pounds were analyzed through CTD’s batch query (with
chemical names listed according to CTD inventory): chromium
hexavalent ion (CAS 18540-29-9), potassium chromate(VI) (CAS
7789-00-6), and sodium bichromate/sodium dichromate (CAS
10588-01-9) (CTD, 2016). Note that studies using SDD (CAS 7789-
12-0) were annotated to sodium dichromate/sodium bichromate
in CTD. In order to identify which chemical-gene/protein inter-
actions were from in vitro study designs, all study titles and
abstracts were manually reviewed through PubMed (NCBI,
2016). All chemical-gene/protein interactions were used, includ-
ing alterations in gene expression, protein expression, and pro-
tein activation.
Pathway enrichment and upstream regulator analysis. Pathway
enrichment analysis was carried out on in vitro (CTD) and in vivo
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(see below) data using the IngenuityVR Pathway Analysis (IPA)
Knowledgebase (v27821452, IngenuityVR Systems, Redwood City,
CA) with the aim of identifying canonical pathways associated
with responses to Cr(VI) exposure. The Ingenuity database pro-
vides a collection of biological interactions and functional anno-
tations created from millions of individually modeled
relationships between proteins, genes, complexes, cells, tissues,
drugs, and disease curated from full-text review of articles from
scientific journals. The knowledgebase includes 650 canonical
pathways, which are well-characterized metabolic and cell sig-
naling pathways curated and drawn from expert review of jour-
nal articles, review articles, text books, and the Encyclopedia of
Human Genes and Metabolism (HumanCyc). Consistent with
IPA recommended best practices, statistical significance of each
canonical pathway was calculated using a right-tailed Fisher’s
exact test using a competitive null hypothesis. Pathways with
p< .05 were considered significant and included for further
analysis. Multiple test corrected p-values of pathway enrich-
ment (using the Benjamini and Hochberg multiple test correc-
tion) were also calculated.
Molecular upstream regulators were also computationally
predicted using the Ingenuity Knowledgebase, using previously
published methods (Kramer et al., 2014). Activation Z-scores
were generated to predict the activation states of predicted
upstream regulators that could explain the observed gene/pro-
tein expression changes. p-Values were also produced using the
Fisher’s Exact Test to measure whether there was a statistically
significant overlap between the Cr(VI)-responsive molecules
and the molecules that are regulated by an upstream regulator.
In order to be predicted as a regulator of the observed molecular
changes, upstream regulators were required to have Z-score >
62 and p < .05.
In vivo study design. To compare in vitro responses to in vivo
responses in a primary site of Cr(VI)-induced tumorigenesis, a
toxicogenomic analysis was carried out in duodenal tissue of
mice exposed to Cr(VI) via drinking water for 13 weeks. These
data have been previously described and analyzed (Kopec et al.,
2012a,b), but were re-processed and analyzed here using
updated methods, tools, and databases for interpretation (see
below). Tissues used for toxicogenomic assessment were from
animals exposed to varying concentrations of Cr(VI) in the form
of SDD for 7 or 90 days, as previously described (Thompson
et al., 2011, 2012).
As described by Thompson et al. (2011, 2012), dose formula-
tions were prepared at concentrations of 0.3, 4, 14, 60, 170, and
520 mg/l SDD (CAS 7789-12-0) in tap water, which is equivalent
to 0.1, 1.4, 5, 20.9, 59.3, and 180 ppm Cr(VI). On the first, third,
fifth, and seventh (final) batch preparations, samples of formu-
lations for each dose group, including the control, were col-
lected and analyzed for Cr(VI) content at Brooks Rand
Laboratories (Seattle, WA) in accordance with EPA Method SW-
7196A. Batch preparations found to differ from the target con-
centration by 610% were not used.
Details regarding animals, vendors, and animal husbandry
were described previously (Thompson et al., 2011, 2012). In brief,
female B6C3F1 mice (Charles River, Raleigh, NC) were received
at 4–5 weeks of age and allowed to acclimate for 2 weeks. Mice
were 13.3–22.9 g of weight at the start of exposure. All animals
were allowed ad libitum access to irradiated NTP-2000 chow
(Zeigler Bros., Gardners, PA) and drinking water (including test
article) until study termination at days 8 or 91 of exposure. The
in-life portion of these studies were conducted at Southern
Research Institute (Birmingham, AL), the same research facility
that conducted the NTP Cr(VI) bioassays (NTP, 2007, 2008).
Preparation of mouse duodenum samples was carried out by
collecting and flushing intestinal sections with ice-cold phos-
phate buffered saline. Duodenal sections were cut longitudi-
nally, and the epithelium was scraped using sterile plastic
spatulas (VWR International) into vials containing TRIzol
(Invitrogen, Carlsbad, CA), snap-frozen in liquid nitrogen, and
stored at 80 C. These frozen tissue samples were homogen-
ized using a Mixer Mill 300 tissue homogenizer (Retsch,
Germany). Total RNA was isolated according to the manufactur-
er’s TRIzol extraction protocol with an additional acid phenol:-
chloroform extraction. Isolated RNA was resuspended in RNA
storage solution (Ambion Inc., Austin, TX), quantified, and qual-
ity assessed by evaluation of A260/A280 ratios and by visual
inspection of 1 mg total RNA on a denaturing gel. Only high qual-
ity RNA samples (A260/280> 1.9) were further examined.
Transcriptomic analyses. Gene expression changes resulting from
Cr(VI) exposure in duodenal tissues were examined using
mouse 4 44 K Agilent whole-genome oligonucleotide microar-
rays (version 1, Agilent Technologies, Inc., Santa Clara, CA). The
tissue samples and microarrays were processed shortly after
collection (ie, ca. 2012), and data were previously analyzed using
posterior probabilities based on an empirical Bayes method
using model-based t-values and genes filtered using fold change
61.5 and P1(t) value> 0.999 (Kopec et al., 2012a; Kopec et al.,
2012b). In the current study, microarray data were re-analyzed
using methods consistent with microarray assessment guide-
lines for use in risk assessment (Bourdon-Lacombe et al., 2015).
Microarrays incorporated independent labeling of each sample
with two different dyes that were scanned using a GenePix
4000B scanner at 532 nm for Cy3 labeling (green dye), and
635 nm for Cy5 labeling (red dye). The mRNA microarray data
were analyzed by pulling data for the median Cy3 dye signal,
because the Cy5 dye signal has been shown to be susceptible to
laboratory-introduced biases/errors (eg, ozone) (Fare et al., 2003).
Microarray data quality was assessed by reviewing probe signal
intensity distributions and through principal component analy-
sis (R v3.2.4) (Thompson et al., 2016). Microarray data are pub-
licly available at www.Cr6study.info and NCBI’s Gene
Expression Omnibus, accessible through GEO Series accession
number GSE87262 (Edgar et al., 2002).
Microarray data were normalized by quantiles (Partek
Genomics Suite, St Louis, Missouri), and background noise was
eliminated by removing mRNA probes with signal intensities
less than the median signal across the majority of samples.
RNA samples were assessed in biological triplicate in all dose
groups (0, 0.03, 4, 14, 60, 170, and 520 mg/l SDD at day 8 and day
91) except for the 4 mg/l SDD exposure group from day 91, which
was analyzed in biological duplicate due to potential microarray
quality issues. Statistical comparisons were carried out using
analysis of variance (ANOVA) between exposed versus unex-
posed samples across all doses. Differentially expressed genes
(DEGs) were defined as those with a significant difference in
mRNA levels between exposed versus unexposed samples with
a fold change of 62 (average exposed vs average unexposed)
and FDR q< 0.05 (Storey, 2003). These methods and statistical
parameters are similar to those implemented in recent publica-
tions using Agilent array data (Bartman et al., 2014; Rager et al.,
2014) and are in line with current guidelines for microarray
analyses (Bourdon-Lacombe et al., 2015). A subset of DEGs iden-
tified in the current analysis were confirmed by comparing to
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quantitative real-time polymerase chain reaction (qRT-PCR)
results in the previously published analyses (Kopec et al., 2012a).
Dose–response modeling of in vivo transcriptomic changes. Dose–
response modeling of the DEGs associated with Cr(VI) exposure
in the mouse duodenum was conducted with BMDExpress v1.4
using methods previously detailed (Moffat et al., 2015; Yang
et al., 2007). Briefly, analyses were carried out on the lists of
DEGs (represented by their respective microarray probesets)
against Cr(VI) dose (mg SDD/L)1 using four models: Hill, power,
linear, and 2 polynomial. The models were run assuming con-
stant variance, and a benchmark response (BMR) factor of 1.349
was used, representing the number of standard deviations
required to shift the mean transcriptional response 10% over
the assumed background rate of response, defining the bench-
mark dose (BMD). Models with the best fit were selected as
those that (1) described the data with the least complexity,
(2) had a nested likelihood ratio test p< .05, and (3) had the low-
est Akaike information criterion (AIC). The Hill model was con-
sidered only when the k parameter (representing the slope) was
more than one third of the lowest dose tested, in order to avoid
artificial minimization of BMDs. Other parameters used in the
analysis included setting the maximum iterations to 250 and
the confidence level to 0.95. Probesets were removed if they
showed either BMD/BMDL (BMD lower confidence limit) ratios
>20, BMD values less than 10-fold below the lowest SDD con-
centration tested, and/or BMD values greater than the highest
concentration tested in order to avoid model extrapolation. In
order for the models to adequately describe potential dose–
response trends in gene expression, curves were required to
have goodness-of-fit p> .1 (likelihood ratio test) (Moffat et al.,
2015; Yang et al., 2007). Genes showing adequate dose–response
curve fits were identified as showing dose–response relation-
ships with Cr(VI) exposure.
Pathway and upstream regulator analysis of in vivo transcriptomic
changes. Pathway enrichment analyses of the DEGs showing
dose–response relationships with Cr(VI) exposure were carried
out using IPA, as described above. Pathways with enrichment
p< .05 were included for further analysis, paralleling the statis-
tical filters used in toxicogenomics-based analyses used for
chemical risk assessment purposes (Farmahin et al., 2016;
Jackson et al., 2014; Moffat et al., 2015). To provide a specific
example, a recent publication reviewed multiple approaches for
calculating points of departure using transcriptomic data,
wherein all approaches used BMDs calculated from IPA path-
ways with enrichment p< .05 (Farmahin et al., 2016). Multiple
test corrected p-values of enrichment were also calculated and
reported in the current analysis.
The resulting pathways and their related molecules were
extracted, BMD values for each pathway-relevant molecule
were pulled, and overall pathway-level median BMD values
were calculated using R (v3.2.4). In the case that multiple probes
showed adequate dose–response relationships to Cr(VI) for the
same gene, probes with the highest goodness-of-fit p-value
were used in calculating median BMD values. For data interpre-
tation purposes, enriched canonical pathways were also organ-
ized into larger categories in an objective manner, using
annotations provided by the Ingenuity’s Signaling Pathway
Categories. Pathway-level findings were linked to previously
published histopathological findings in order to phenotypically
anchor the observed transcriptomic responses to potential key
events involved in Cr(VI) MOA. Potential key events involved in
Cr(VI) MOA were identified by reviewing MOAs suggested
through recent peer-reviewed publications (McCarroll et al.,
2010; Thompson et al., 2011). Among the available signaling
pathway categories, four were involved in potential key events:
(1) cell stress and injury (including genotoxic responses),
(2) apoptosis, (3) cell growth, proliferation and development,
and (4) cancer (as the eventual adverse outcome). Molecular
upstream regulators of the DEGs were computationally pre-
dicted using methods described in the above text.
RESULTS
Tox21 Results Showed Cr(VI)-Induced Changes in TP53 Activation
and Cell Proliferation
Cr(VI) (as SDD) data were available across 113 Tox21 assay end-
points, 40 of which were identified as active in response to SDD
exposure (Table 1). An important aspect to consider when inter-
preting HTS data is the concentration at which cytotoxicity
occurs, as activity that occurs near or above concentrations
inducing cytotoxicity may reflect non-specific assay activation
or activity associated with general disruption of cellular machi-
nery that can lead to cell stress/death (ie, “cytotoxic signal
burst”), rather than disruption of specific biomolecular targets
or pathways (Judson et al., 2016). SDD caused cytotoxicity in the
active assays at a median AC50 of 30.3 mM. Rather than directly
comparing the chemical-assay versus cytotoxicity AC50, a statis-
tical approach was implemented through a Z-score filter, as
implemented in recent publications (Auerbach et al., 2016;
Judson et al., 2016). Of the 40 active assay endpoints, 20 showed
Z-scores> 2 (Tables 1 and 2), representing assay endpoints that
likely indicate specific disruption of biomolecular targets or
pathways rather than cytotoxicity interference.
Interpreting HTS findings in the context of the TKCC, two
key characteristics showed the highest number (n¼ 4) of active
assay endpoints with Z-scores> 2: genotoxic (KCC#2) and cell
proliferation, cell death, or nutrient supply (KCC#10). All of the
active assays mapping to KCC#2 were indicative of human
tumor protein 53 (TP53) DNA binding activation (Table 2). These
assay data were generated with an inducible reporter (detected
with fluorescence intensity signals by GAL4 beta lactamase
reporter gene technology) using a human intestinal cell line
(HCT116) treated with SDD at varying concentrations (0–100 mM)
for 24 h. It is important to note that although p53 activation can
be triggered by DNA damage (Levine et al., 2006), these TP53
assay endpoints did not directly measure genotoxicity. All of
the active assays mapping to KCC#10 represented cell viability
assay endpoints that were categorized with the biological proc-
ess target of cell proliferation (Table 2). In addition to the assays
showing activity, it is also important to note that inactive assay
endpoints mapped to other KCCs, including chronic inflamma-
tion (KCC#6) and modulation of receptor-mediated effects
(KCC#8), showing the following number of active/total assays:
0/1 and 1/20 (Table 1).
In Vitro Responses to Cr(VI) Identified Through CTD
To determine whether Tox21 HTS results are consistent with
other published in vitro findings, the CTD was queried for
chemical-gene/protein interactions relevant to Cr(VI) exposure
and filtered for interactions identified in vitro. Querying
1 PBPK models for Cr(VI) are available; however, the dose met-
ric for flux of Cr(VI) through intestinal enterocytes into por-
tal blood is not comparable to in vitro cell systems and thus
the PBPK model was not employed.
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Table 1. Summary of the Number of HTS Assay Endpoints Used to Evaluated Cr(VI) Bioactivity Through the Tox21 Database, as Organized
According to the TKCC
TKCC Number TKCC Name Number of Assay
Endpoints Tested
Number of Active
Assay Endpoints
Number of Active
Assays Endpoints
with Z-score>2
1 Act as an electrophile either directly or after metabolic activation 1 1 1
2 Is genotoxic 5 5 4
3 Alter DNA repair or cause genomic instability 0 NAa NA
4 Induce epigenetic changes 0 NA NA
5 Induce oxidative stress 3 1 1
6 Induce chronic inflammation 1 0 0
7 Be immunosuppressive 0 NA NA
8 Modulate receptor-mediated effects 20 7 1
9 Cause immortalization 0 NA NA
10 Alter cell proliferation, cell death, or nutrient supply 22 13 4
NA Not mapped to TKCC 61 13 9
Sum 113 40 20
TKCC¼Ten Key Characteristics of Carcinogens as described in Smith et al. (2016) and mapped according to IARC monograph volume 112 (IARC, 2015).
aNA, not applicable.
Table 2. Tox21 Active Assay Endpoints Associated With SDD Treatment In Vitro, Organized According to the TKCC
TKCC
Number
Assay Endpoint Name AC50 (mM) Z-score
a Gene
Target
Organism Tissue Cell Type Biological Process Target
1 TOX21_Aromatase_Inhibition 2.05 5.73 CYP19A1 Human Breast MCF-7 Regulation of transcription
factor activity
2 TOX21_p53_BLA_p5_ratio 7.39 3.00 TP53 Human Intestinal HCT116 Regulation of transcription
factor activity
2 TOX21_p53_BLA_p1_ratio 4.59 4.02 TP53 Human Intestinal HCT116 Regulation of transcription
factor activity
2 TOX21_p53_BLA_p2_ratio 4.44 4.09 TP53 Human Intestinal HCT116 Regulation of transcription
factor activity
2 TOX21_p53_BLA_p3_ratio 2.58 5.24 TP53 Human Intestinal HCT116 Regulation of transcription
factor activity
5 TOX21_ARE_BLA_agonist_ratio 11.00 2.16 NFE2L2 Human Liver HepG2 Regulation of transcription
factor activity
8 TOX21_GR_BLA_Antagonist_ratio 5.15 3.77 NR3C1 Human Cervix HeLa Regulation of transcription
factor activity
10 TOX21_p53_BLA_p4_viability 11.77 2.01 NAb Human Intestinal HCT116 Cell proliferation
10 TOX21_p53_BLA_p3_viability 8.63 2.67 NA Human Intestinal HCT116 Cell proliferation
10 TOX21_GR_BLA_Antagonist_viability 2.86 5.02 NA Human Cervix HeLa Cell proliferation
10 TOX21_AR_BLA_Antagonist_viability 1.51 6.39 NA Human Kidney HEK293T Cell proliferation
NA TOX21_ARE_BLA_Agonist_ch2 10.50 2.26 NA Human Liver HepG2 Regulation of transcription
factor activity
NA TOX21_PPARd_BLA_agonist_ch2 8.37 2.74 NA Human Kidney HEK293T Regulation of transcription
factor activity
NA TOX21_GR_BLA_Antagonist_ch2 6.46 3.29 NA Human Cervix HeLa Regulation of transcription
factor activity
NA TOX21_p53_BLA_p1_ch2 6.02 3.44 NA Human Intestinal HCT116 Regulation of transcription
factor activity
NA TOX21_AR_BLA_Agonist_ch2 5.54 3.62 NA Human Kidney HEK293T Regulation of transcription
factor activity
NA TOX21_p53_BLA_p5_ch2 3.78 4.43 NA Human Intestinal HCT116 Regulation of transcription
factor activity
NA TOX21_p53_BLA_p2_ch2 2.93 4.97 NA Human Intestinal HCT116 Regulation of transcription
factor activity
NA TOX21_p53_BLA_p3_ch2 2.08 5.70 NA Human Intestinal HCT116 Regulation of transcription
factor activity
NA TOX21_TR_LUC_GH3_Antagonist 0.84 7.64 NA Rat Pituitary
gland
GH3 Regulation of transcription
factor activity
TKCC¼Ten Key Characteristics of Carcinogens as described in Smith et al. (2016) and mapped according to IARC monograph volume 112 (IARC, 2015).
aZ-scores are based on comparing chemical-assay AC50 against chemical cytotoxicity distribution, with SDD showing a median cytotoxicity AC50 of 30.3mM.
bNA, not applicable.
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chromium hexavalent ion, potassium chromate(VI), and
sodium bichromate/sodium dichromate resulted in the identifi-
cation of 525, 5168, and 641 in vitro chemical-gene/protein inter-
actions from 70, 13, and 19 references, respectively
(Supplementary Table 1). The majority of these chemical-gene/
protein interactions (5757 out of 6334 interactions) represented
changes in gene expression. Together, a total of 3502 unique
molecules were identified as altered by in vitro exposure to
Cr(VI) through CTD. Of these molecules, 2028 were identified by
two or more references and 435 were identified by three or more
references. Notably, TP53 alterations associated with in vitro
Cr(VI) exposure were identified in 10 studies.
In Vitro Responses to Cr(VI) Are Enriched for Apoptosis, p53, and
DNA Damage Response Signaling
Pathway enrichment analysis was carried out using the
IngenuityVR Pathway Analysis knowledgebase with the aim of
identifying canonical pathways associated with responses to
Cr(VI) exposure in vitro. Analyses were completed for the genes/
proteins with alterations identified through the CTD repository,
using three separate lists: (1) molecules identified by 1 study
(n¼ 3502), (2) molecules identified by 2 studies (n¼ 2028), and
(3) molecules identified by 3 studies (n¼ 435). Due to the large
number of molecules shown to be altered by Cr(VI) exposure,
many canonical pathways were identified as enriched
(Supplementary Table 2). Amongst the most significantly
enriched pathways across all three lists were apoptosis signal-
ing (p¼ 3.98  1013, p¼ 5.01  1011, and p¼ 6.31  1017 for
molecules identified by 1 study, 2 studies, and 3 studies,
respectively), ATM (ataxia telangiectasia mutated) signaling
(p¼ 1.00  1012, 1.58  1015, and 1.58  1015), and p53 signal-
ing (p¼ 1.58  1013, 3.98  1015, and 7.94  1015). Notably,
these pathways also showed significance after correction for
multiple testing (Supplementary Table 2). These findings dem-
onstrate consistency between in vitro Tox21 HTS results (p53
activity and cell proliferation/cell death alterations) and in vitro
CTD results (alterations in p53, DNA damage, and apoptosis).
Transcriptomic Changes Associated With In Vivo Exposure to Cr(VI)
Transcriptomic analyses were carried out using mouse duode-
num tissue, the target tissue shown to undergo tumorigenesis
with the highest incidence in mice chronically exposed to high
doses of Cr(VI) via drinking water (NTP, 2008). Transcriptomic
analyses, along with qRT-PCR verification, were published pre-
viously using an empirical Bayes method (Kopec et al., 2012a,b).
The present updated analysis includes advancements in
genomics-based tools and methods specifically relevant to risk
assessment. Notably, the new analyses were consistent with
previous qRT-PCR results (Supplementary Figure 1).
Transcriptomic analysis identified a total of 3029 genes (repre-
sented by 4041 probe sets) with differential expression resulting
from 7 days of exposure in at least one dose group
(Supplementary Table 3), and a total of 1099 genes (represented
by 1449 probe sets) with differential expression resulting from
90 days of exposure (Supplementary Table 4). In general, the
number of DEGs with altered expression increased with increas-
ing Cr(VI) exposure concentrations (Figure 1). Notably, signifi-
cant gene expression alterations did not occur until 60 mg/l SDD
(20 ppm Cr(VI)) in mice exposed for 90 days (Figure 1B).
Dose–Response Analysis of Transcriptomic Changes
DEGs associated with Cr(VI) treatment in the mouse duodenum
were analyzed for dose-dependent changes using BMDExpress,
with the goals of identifying genes that show dose-dependent
changes in expression and comparing estimated doses at which
changes in pathways relevant to Cr(VI) key events occur. Out of
the 3029 DEGs resulting from 7 days of exposure in at least one
dose group, 938 showed dose-dependent changes (Figure 1C,
Supplementary Table 5). The median BMD estimate was
42 mg SDD/l, and the median BMDL estimate was 26 mg SDD/l
(Table 3). Out of the 1099 DEGs resulting from 90 days of
exposure in at least one dose group, 665 showed dose-
dependent changes (Figure 1D, Supplementary Table 5). The
median BMD estimate was 38 mg SDD/l, and the median
BMDL estimate was 28 mg SDD/l (Table 3). Example dose–
response curve plots are provided in supplementary material
(Supplementary Figure 2).
Pathway Enrichment Analysis of In Vivo Dose-Dependent Genes
The DEGs showing good dose–response curve fits were analyzed
in the context of canonical pathways. A total of 55 pathways
were identified as associated with genes showing dose-
dependent changes after 7 days of exposure, and 62 pathways
with genes showing dose-dependent changes after 90 days of
exposure (Supplementary Table 2). Median BMD values
across all molecules in each pathway were calculated, as
used in previous transcriptomic BMD assessments (Thomas
et al., 2012b), and resulted in the generation of pathway-level
median BMD estimates (Supplementary Table 6). These
pathway-level median BMD estimates ranged from 8 to
108 mg SDD/l for the day 8 results, and 18–132 mg SDD/l for
the day 91 results (Table 3).
The individual canonical pathways associated with Cr(VI)
exposure were organized in an objective and reproducible man-
ner into larger signaling pathway categories, as provided by the
Ingenuity knowledgebase (Supplementary Table 6). Among the
available signaling pathway categories, four are involved in
potential Cr(VI) MOA key events, with key events extracted from
previous Cr(VI) MOA reviews (McCarroll et al., 2010; Thompson
et al., 2011): (1) cell stress and injury, (2) apoptosis, (3) cell
growth, proliferation and development, and (4) cancer (as the
eventual adverse outcome). Notably, the cell stress and injury
pathway includes genotoxicity, which was a major early key
event proposed by McCarroll et al. (2010). All enriched pathways
that relate to these categories are shown in Table 4 with
pathway-level median BMD and BMDL estimates. In general,
pathways related to cell stress and injury included genes with
majority increased expression associated with Cr(VI) exposure.
Pathways related to the larger category of apoptosis (which
included the canonical apoptosis pathway, among others) were
not enriched at day 8; yet showed enrichment at day 91. These
pathways included genes with majority decreased expression
associated with Cr(VI), suggesting that decreased apoptosis-
related signaling occurred. Consistent with this finding, almost
all pathways related to cell growth, proliferation and develop-
ment included genes with majority increased expression at day
8 and 91. Evaluation of the pathway-level median BMD esti-
mates showed that at day 8, pathway alterations related to key
events occurred between 19 and 82 mg SDD/l. The median
pathway-level BMD estimates at day 91 were higher than day 8,
ranging from 29 to 132 mg SDD/l for pathways related to key
events (Table 3).
Phenotypic Anchoring of In Vivo Transcriptomic Findings
The pathway categories identified as associated with transcrip-
tomic responses to Cr(VI) are consistent with previously pub-
lished histopathological data (Table 5). For instance, pathways
related to increased cell stress and injury are consistent with
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intestinal villus atrophy and blunting that have been observed
in mice exposed to 60 mg SDD/l for 90 days (Cullen et al., 2016).
Decreased signaling related to apoptosis and increased signal-
ing related to cell growth, proliferation, and development is also
supported at the histopathology level through observed
increases in intestinal crypt length in exposed mice (Thompson
et al., 2015a,b). In vivo duodenal micronucleus (MN) assays indi-
cate a lack of genotoxicity in the crypt compartment (O’Brien
et al., 2013; Thompson et al., 2015b), which is also consistent
with transcriptomic responses showing a lack of p53/DNA dam-
age response signaling alterations. Moreover, these findings are
also consistent with X-ray fluorescence mapping of chromium
in the unstained duodenal sections from mice exposed to
180 ppm Cr(VI) for 7 and 90 days (Thompson et al., 2015a,b),
which indicates that chromium localizes to intestinal villi, but
not the crypt regions where cell proliferation occurs.
Alterations in cancer signaling can potentially be anchored
to the adverse outcome of tumor formation in the mouse duo-
denum tissue observed in 2-year Cr(VI) bioassays (NTP, 2008);
however, pre-neoplastic lesions have not been observed in mice
or rats exposed to 180 ppm Cr(VI) for 90 days (NTP, 2007;
Thompson et al., 2011, 2012), and tumors were not observed in
mice until well after one year of exposure (NTP, 2008).
Therefore, caution is needed when anchoring the “cancer” path-
way changes because the time- and dose-matched tissues were
not diagnosed as neoplastic or pre-neoplastic. For example, the
increases in cancer-related signaling observed at day 8
(Figure 2A) largely resulted from increased expression of matrix
metalloproteases, including Mmp2, Mmp7, Mmp9, Mmp10, and
Mmp13. Notably, Mmp10 and Mmp13 also showed dose-
dependent increases in expression at day 91. These genes are
known to be involved in tissue remodeling, cell migration,
immune cell recruitment, and angiogenesis (Klein and Bischoff,
2011), representing functions that can overlap with carcinogen-
esis. Matrix metalloproteases also show increased expression in
the intestine linked to tissue remodeling in gluten enteropathy
(ie, celiac disease) (Ciccocioppo et al., 2005; Salmela et al., 2001),
representing an intestinal disease state that shares some
Figure 1. Genes with differential expression associated with exposure to Cr(VI) in the mouse duodenum. The number of DEGs identified by comparing exposed versus
unexposed samples (FC2, q<0.05) after (A) 7 days and (B) 90 days of exposure to varying concentrations of Cr(VI) (as SDD in drinking water). DEGs that showed both
differential expression in exposed versus unexposed samples (FC2, q<0.05) and dose-dependent changes in expression identified through BMD modeling (curve fit
p> .10) after (C) 7 days and (D) 90 days of exposure to Cr(VI). Heat maps display fold change (FC) in expression (exposed/unexposed) for each DEG, with the concentra-
tions of SDD (in mg/l) listed on the top.
Table 3. BMD and BMDL Estimates for In Vivo Transcriptomic Responses to Cr(VI) in the Mouse Duodenum
Day 8 BMD Estimates
Mean, Median
(Min–Max)
Day 8 BMDL Estimates
Mean, Median
(Min–Max)
Day 91 BMD Estimates
Mean, Median
(Min–Max)
Day 91 BMDL Estimates
Mean, Median
(Min–Max)
DEGs that show dose-dependent changes
63, 42 (0.045–505) 40, 26 (0.004–337) 51, 38 (0.397–513) 35, 28 (0.052–293)
Median pathway-level BMD values across all enriched canonical pathways
51, 52 (8–108) 33, 30 (2–71) 48, 45 (18–132) 33, 31 (13–97)
Median pathway-level BMD values across categories relevant to key events
Cell stress and injury 38, 44 (19–60) 25, 28 (9–43) 41, 39 (34–47) 30, 30 (23–34)
Apoptosis None None 54, 44 (29–132) 39, 31 (20–97)
Cell growth, proliferation and development 35, 26 (19–71) 21, 14 (9–47) 43, 45 (29–61) 33, 34 (21–51)
Cancer 80, 80 (79–82) 59, 59 (52–67) 42, 42 (39–44) 31, 31 (30–31)
Values are provided in mg SDD/L in drinking water.
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common histopathological phenotypes with Cr(VI) (eg, villus
atrophy and crypt hyperplasia). It is notable that other enriched
pathways that were not annotated to the larger “cancer” signal-
ing pathway (through IPA) could be argued to play a role in car-
cinogenesis. However, only pathways annotated to “cancer”
through the IPA knowledgebase were included in this category
to maintain objectivity and reproducibility (although all results
are detailed in Supplemental Table 6).
Comparison of In Vitro versus In Vivo Pathways and Upstream
Regulators Associated With Cr(VI)
Comparing the in vitro versus in vivo pathway-level responses to
Cr(VI) indicates that both experimental models exhibited signal-
ing related to cell death and cell proliferation (Supplementary
Table 2). However, despite the use of a p< 0.05 pathway enrich-
ment filter (representing a less stringent filter than a multiple
test corrected p-value), pathway changes related to p53/DNA
damage were evident in vitro but not in vivo. This was specifi-
cally evidenced by the canonical apoptosis pathway including
changes relevant to p53/DNA damage in vitro, but not in vivo
(Figure 2A and 2B). Furthermore, the canonical p53 signaling
pathway showed enrichment in vitro but not in vivo (Figure 2C
and 2D). It is worth emphasizing that this lack of p53 signaling
was observed across a wide range of in vivo exposure levels
(non-responsive, non-carcinogenic, and carcinogenic concen-
tration) and durations (7 and 90 days of exposure).
Other canonical pathways relevant to DNA damage that
were associated with only in vitro responses included ATM sig-
naling, cell cycle: G2/M DNA damage checkpoint regulation,
DNA damage-induced 14-3-3sigma signaling, DNA double-
strand break repair by homologous recombination, DNA double-
strand break repair by non-homologous end joining, mismatch
repair in eukaryotes, and role of BRCA1 in DNA damage
response (Supplementary Table 2). A canonical pathway
enriched at day 8 was relevant to DNA damage in vivo, the
nucleotide excision repair pathway (Table 4, Supplementary
Table 2). This pathway consisted of eight genes showing
increased expression associated with Cr(VI), all of which are
also involved in general DNA transcription and cell cycle signal-
ing: cyclin H (Ccnh), general transcription factor genes (Gtf2h1
Table 5. Phenotypic Evidence for Intestinal Transcriptomic Responses Found in Mice Exposed to SDD (520 mg SDD/l) Through Drinking Water
In Vivo Transcriptomic Findings In Vivo Phenotypic Evidence References
7 days of exposure
Increased signaling related to cell growth,
proliferation and development
Cell proliferation observed through crypt epithelial
hyperplasia in transverse duodenal H&Eb stained
sections
(Thompson et al., 2011)
Cell proliferation observed through increased numbers
of crypt enterocytes in Feulgen stained Swiss roll duo-
denal sections
(Thompson et al., 2015b)
Increased signaling related to cell stress and injury
(including one pathway relevant to genotoxicity,
nucleotide excision repair pathwaya)
Lack of genotoxicity observed through lack of crypt
micronucleus induction in Feulgen stained transverse
duodenal sections
(O’Brien et al., 2013)
Lack of genotoxicity observed through lack of crypt
micronucleus induction in Feulgen stained Swiss roll
duodenal sections
(Thompson et al., 2015b)
Tissue dosimetry observed through XRFc mapping, indi-
cating chromium localized to the intestinal villi, and
little (if any) in the crypt
(Thompson et al., 2015b)
90 days of exposure
Increased signaling related to cell growth, prolifera-
tion and development
Cell proliferation observed through crypt epithelial
hyperplasia in transverse duodenal H&E stained
sections
(Cullen et al., 2016;
Thompson et al., 2011)
Cell proliferation observed through increased numbers
of crypt enterocytes in Feulgen stained transverse
duodenal sections
(O’Brien et al., 2013)
Cell proliferation observed through increased crypt
length (mm) in Feulgen stained transverse duodenal
sections
(Thompson et al., 2015a)
No enrichment for DNA damage response pathways Lack of genotoxicity observed through lack of crypt
micronucleus induction in Feulgen stained transverse
duodenal sections
(O’Brien et al., 2013)
Tissue dosimetry observed through XRF mapping, indi-
cating chromium localized to the intestinal villi, and
little (if any) in the crypt
(Thompson et al., 2015a)
Significant, robust changes in transcriptomic profiles
are consistent with tissue dosimetry
Tissue dosimetry observed through mass spectrometry,
indicating increased total chromium in the
duodenum
(Thompson et al., 2011)
aThe nucleotide excision repair pathway consisted of eight genes showing increased expression associated with Cr(VI), all of which are also involved in general DNA
transcription and cell cycle signaling: cyclin H (Ccnh), general transcription factor genes (Gtf2h1 and Gtf2h3), RNA polymerase II genes (Polr2e, Polr2f, Polr2h, Polr2l), and
replication protein A3 (Rpa3).
bH&E, Haemotoxylin and Eosin.
cXRF, X-ray fluorescence microscopy.
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and Gtf2h3), RNA polymerase II genes (Polr2e, Polr2f, Polr2h,
Polr2l), and replication protein A3 (Rpa3). The increased expres-
sion levels of these genes at day 8 is therefore consistent with
the finding that proliferative responses and tissue remodeling is
likely occurring in these tissues.
As TP53 alterations often occur post-translationally (Levine
et al., 2006), it was important to also consider the potential for
TP53 changes resulting from Cr(VI) exposure at the protein level
through transcription factor enrichment analysis. This
upstream regulator prediction analysis provided further
Figure 2. Apoptosis and p53 signaling related to Cr(VI) exposure. Molecules altered by in vitro exposure to Cr(VI), as identified through HTS Tox21 data and CTD, are
enriched for (A) apoptosis signaling and (C) p53 signaling. Genes showing dose-dependent changes in expression after 90 days of exposure to Cr(VI) in the mouse duo-
denum are enriched for (B) apoptosis signaling but not (D) p53 signaling. No genes relevant to p53/DNA damage signaling within the canonical apoptosis pathway
showed altered expression in vivo, as marked by the red asterisks. Note that pathways associated with 7 days of exposure to Cr(VI) in the mouse duodenum are not dis-
played, as there was no enrichment for apoptosis or p53 signaling in these tissues.
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evidence supporting TP53 as a likely transcriptional regulator of
in vitro responses (activation Z-score¼ 4.51, p¼ 3.92  1078 for
molecules identified by at least one study in CTD). However,
TP53 was not within the list of 250 molecules predicted to
potentially regulate in vivo responses to Cr(VI) (Supplementary
Table 7). These findings further support the lack of involvement
of TP53 in intestinal cancer resulting from Cr(VI) oral exposure
in mice.
DISCUSSION
This study informs the MOA underlying intestinal tumors
induced by Cr(VI) in mice through the evaluation of HTS data, a
large database of published in vitro responses to Cr(VI) (ie, CTD),
and toxicogenomics data from the intestine of mice exposed to
Cr(VI). HTS data from the Tox21 consortium were determined to
be generally consistent with in vitro Cr(VI) data in the open liter-
ature, accumulated through CTD, exemplifying the utility of
publicly available HTS data in identifying in vitro responses to
chemicals. Analysis of these data showed that in vitro Cr(VI)
exposure was associated with alterations in p53 signaling and
cell death/proliferation signaling. In vivo transcriptomic data for
Cr(VI), in contrast, were associated with changes in cell death/
proliferation, but not p53 signaling, in the small intestine.
Consistent with earlier analyses of transcriptomic responses in
the duodenum (Kopec et al., 2012a,b), this updated analysis sup-
ports a non-mutagenic MOA for Cr(VI)-induced intestinal can-
cer. These in vivo transcriptomic analyses are consistent with
phenotypic anchoring: histopathological evidence of regenera-
tive hyperplasia, lack of in vivo genotoxicity, and relatively late
onset of tumor formation.
Analyses from the present study found that transcriptomic
responses in the mouse intestine showed enrichment for path-
ways related to increased cell stress and injury, paralleling phe-
notypic observations of intestinal villus atrophy and blunting in
exposed mice (Cullen et al., 2016). Gene expression profiles were
generally decreased for pathways involved in apoptosis and
increased for pathways related to cell growth, proliferation, and
development. These findings are supported by histopathology
indicating increased crypt length in exposed mice (Thompson
et al., 2015a,b). Cancer signaling was also associated with the
in vivo transcriptomic responses at day 8 and 91; however,
exposed mice did not exhibit tumors until after at least one year
of exposure to 30 ppm Cr(V) in drinking water (NTP, 2008).
Increased cancer-related signaling at day 8 largely reflected
increased expression of matrix metalloproteases, which are
involved in functions that can overlap with carcinogenesis,
including tissue remodeling, cell migration, immune cell
recruitment, and angiogenesis (Klein and Bischoff, 2011).
Specifically in the intestine, matrix metalloproteases have
shown increased expression related to tissue remodeling in
cases of gluten enteropathy (ie, celiac disease) (Ciccocioppo
et al., 2005; Salmela et al., 2001), an intestinal disease with histo-
pathological changes in common with Cr(VI) (eg, villus atrophy
and crypt hyperplasia). These pathway changes are relevant to
key events involved in Cr(VI) MOA and were estimated to start
at median benchmark concentrations of 19 mg/l SDD [equiva-
lent to 7 ppm Cr(VI)] after 7 days of exposure and 29 mg/l [equiv-
alent to 11 ppm Cr(VI)] SDD after 90 days of exposure. To
provide context for the BMD estimates, the average concentra-
tion of Cr(VI) in U.S. drinking water is 0.001 ppm, and the 95th
upper percentile is 0.0034 ppm (U.S. EPA, 2014).
Recent examples of HTS applications in chemical assess-
ments have involved the use of in vitro HTS data to prioritize
chemical(s) for further toxicological evaluation (Auerbach et al.,
2016; Rotroff et al., 2014). Some prioritization efforts have also
considered the potential for human exposure, and thus show
further applicability to the field of risk assessment (Rager et al.,
2016; Wambaugh et al. 2014; Wetmore et al., 2015). Fewer exam-
ples are currently available showing HTS data interpretation in
the context of regulatory decision making. Recent cancer mono-
graphs published by the International Agency for Research on
Cancer (IARC) represent examples of how HTS data could poten-
tially contribute to the understanding of chemical mechanisms
involved in human carcinogenicity, with specific emphasis on
the TKCCs (IARC, 2015). Previous in vivo cancer prediction mod-
els using ToxCast HTS data have, however, shown limited pre-
dictability (Anthony et al., 2016; Thomas et al., 2012a), and it is
therefore important to consider potential ranges of applicability
and limitations of in vitro HTS data interpretation.
The current study expanded on the application of HTS strat-
egies by first organizing Tox21 data according to the TKCCs, and
identifying KCCs that may be involved in mechanistic events
linking Cr(VI) exposure to cancer. This method resulted in the
identification of two KCCs, genotoxic (KCC#2) and alter cell pro-
liferation, cell death and nutrient supply (KCC#10), that might
have been prioritized for further evaluation in the context of
Cr(VI) MOA. These two categories of molecular responses also
represent key events under consideration in earlier MOA discus-
sions for Cr(VI) (McCarroll et al., 2010; Thompson et al., 2011).
The research described herein revealed evidence primarily for
KCC#10, consistent with a more recently proposed MOA for
Cr(VI) (Thompson et al., 2013), as well as risk assessments based
on these data (Haney, 2015; Health Canada, 2015; TCEQ, 2016).
This retrospective case study therefore demonstrates the poten-
tial utility of HTS data in prioritizing key events for further eval-
uation in chemical MOA, which in turn, after additional
research, may impact chemical safety criteria and regulatory
decision making.
A potential limitation in using HTS data to inform Cr(VI)
MOA was evident after finding that in vitro responses were not
entirely consistent with in vivo responses in the mouse small
intestine, a target tissue of Cr(VI) carcinogenesis. Specifically,
analysis of Tox21 data identified four active assay endpoints for
Cr(VI) in human intestinal cells relevant to p53 transcriptional
activation, which were mapped to genotoxic (KCC#2). Other
in vitro studies identified through CTD corroborate the finding
that p53 pathway alterations occur in response to in vitro expo-
sure to Cr(VI), as evidenced through pathway-level and
upstream regulator prediction analyses. However, analysis of
in vivo transcriptomic responses in the mouse duodenum
showed a clear lack of p53 pathway alterations and potential
TP53 upstream regulator activity.
There are several potential explanations for the differences
between in vitro and in vivo responses to Cr(VI). For instance, the
Tox21 HTS assays evaluating TP53 activation used human
intestinal cancer cells, whereas the in vivo responses evaluated
here were from mouse intestinal non-cancerous tissue. While
both model systems directly absorbed Cr(VI), and both model
systems contain cells that can express and activate TP53, there
could be differences in responses dependent upon species as
well as the cellular disease state (normal vs transformed).
Regarding cell state, it is important to realize that in vitro HTS
methods (acute by nature) are intended to screen for potential
adverse effects and thus should serve as proxies for normal
human tissues. As such, the toxicity comparisons herein
between non-cancerous in vivo tissue and in vitro Tox21 models
ought to be valid if the in vitro models are to have predictive
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value. In support of these comparisons, specifically regarding
TP53, both cancer and non-cancer cells have been shown to
undergo in vitro Cr(VI)-associated DNA damage and eventual
apoptosis dependent upon p53 activation and its upregulation
of downstream targets (Russo et al., 2005). Therefore, the finding
that Cr(VI) altered p53/DNA damage response signaling in vitro
(with Tox21 data from cancer cells and CTD data from cancer
and non-cancer cells) but not in vivo (with non-cancer cells) is
informative towards HTS data interpretation in the context of
in vivo MOA.
Other explanations for the differences between in vitro ver-
sus in vivo responses include Cr(VI) kinetics, cell cycle, exposure
durations (acute versus chronic), components within the
media/surrounding fluid, and intracellular reductants.
Regarding cell cycle, in vitro exposure systems typically evaluate
effects in proliferating cells. In the mouse model, Cr(VI) was
absorbed by mature, non-dividing cells in the intestinal villus
(Thompson et al., 2015a,b). Regarding reduction kinetics, the
intracellular ascorbate levels available to reduce Cr(VI) to Cr(III)
may differ in vitro versus in vivo. In vitro responses to Cr(VI) differ
depending on whether low cellular ascorbate levels are
“restored” to in vivo levels (Luczak et al., 2016). Unrestored cells
treated with Cr(VI) exhibit significant ATM activation possibly
through glutathione (GSH)-mediated Cr(VI) reduction, whereas
restored cells rely more on ascorbate-mediated reduction of
Cr(VI) which does not appear to activate ATM (Luczak et al.,
2016). Considering that rodents synthesize ascorbate, and that
GSH levels and GSH synthesis pathways have been shown to be
upregulated in the duodenum of mice treated with Cr(VI) for 90
days (Kopec et al., 2012a; Thompson et al., 2011), both reduction
pathways are likely active in the mouse. Importantly, p53 activ-
ity is upregulated in vitro in both Asc-restored and non-restored
cells after Cr(VI) exposure (Luczak et al., 2016), which does not
appear to occur in vivo in the duodenum based on the analyses
herein. Moreover, the ATM signaling pathway was identified as
altered through the in vitro analysis but not within the in vivo
transcriptomic responses. These aforementioned differences not
only potentially explain the differential outcomes between
in vitro and in vivo data, but are highly relevant for risk assess-
ment, as the in vivo model more closely recapitulates human dos-
imetry and intestinal tissue structure and can thus inform MOA
to a greater extent than HTS-based toxicity predictions alone.
In conclusion, this study provides an analysis of HTS and
genomics-based data on a compound that is of high interest
from the regulatory perspective. Emerging methods were used
to evaluate the HTS data, including mapping of assays to
TKCCs, incorporation of potential cytotoxicity interference, and
comparison to other publicly available in vitro data to support
findings. Comparing in vitro responses to in vivo transcriptomic
responses, similarities were identified between cell death/pro-
liferation alterations occurring in response to Cr(VI). Differences
in p53/DNA damage signaling pathway alterations were appa-
rent, with p53 pathway changes occurring in vitro but not in vivo.
This example therefore demonstrates both the potential
strengths and limitations of HTS data. Here, we retrospectively
demonstrated that HTS data could be used to identify potential
key events in chemical MOA that may be prioritized for further
evaluation. Still, findings show that target tissue in vivo data
remain a critical component for establishing the MOA for spe-
cific chemical-induced tumor outcomes. Future studies compar-
ing in vitro versus in vivo responses induced by other chemicals
with differing physicochemical properties and target tissues
will further inform potential ranges of applicability for the util-
ity of HTS in predictive toxicology.
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